CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 92 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-11 | Krop Julie Director | Grant or award · Non-Qualified Stock Option (right to buy) | +28,500 | 28,500 | ||
| 2021-03-11 | TOTH A ERNEST JR Interim CFO | Grant or award · Non-Qualified Stock Option (right to buy) | +2,500 | 2,500 | ||
| 2021-03-11 | Marshall Ken W. SVP, Chief Commercial Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-03-11 | BRAENDER LORI J SVP, General Counsel | Grant or award · Non-Qualified Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2021-03-11 | Kendall Keith J CEO and President | Grant or award · Non-Qualified Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2021-03-11 | Taglietti Marco Director | Grant or award · Non-Qualified Stock Option (right to buy) | +28,500 | 28,500 | ||
| 2021-03-11 | Schobel Alexander Mark Chief Innovation/Tech Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +70,000 | 70,000 | ||
| 2021-03-11 | Barber Daniel SVP-Chief Operating Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-03-11 | Boyd Peter E. SVP-Bus. Process & Info. Tech. | Grant or award · Non-Qualified Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2021-03-09 | BRATTON DOUGLAS K 10% owner | Gift | −62,500 | 12,585 | ||
| 2021-02-10 | Schobel Alexander Mark Chief Innovation/Tech Officer | Sale | −23,460 | $6.75 | $158K | 837,000 |
| 2021-02-09 | Schobel Alexander Mark Chief Innovation/Tech Officer | Sale | −11,540 | $6.75 | $78K | 860,460 |
| 2021-02-08 | Schobel Alexander Mark Chief Innovation/Tech Officer | Sale | −40,792 | $6.50 | $265K | 872,000 |
| 2020-12-30 | Kendall Keith J CEO and President | Gift | −1,000 | 638,149 | ||
| 2020-12-30 | Kendall Keith J CEO and President | Gift | +1,000 | 1,000 | ||
| 2020-12-30 | Kendall Keith J CEO and President | Gift | −1,000 | 637,149 | ||
| 2020-12-30 | Kendall Keith J CEO and President | Gift | +1,000 | 1,000 | ||
| 2020-08-18 | Maxwell John T. SVP-Chief Financial Officer | Sale | −3,000 | $8.00 | $24K | 150,614 |
| 2020-06-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise | +333 | 912,886 | ||
| 2020-06-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Shares withheld for taxes | −94 | $4.86 | $457 | 912,792 |
Page 14 of 15 · 300 trades